Rising Payor Influence Means Successful Drug Launches are Rarer
Executive Summary
Growing payor influence on the uptake of high-price products is making successful drug launches far harder to achieve. Payor power varies from one Western market to the next, but all are moving in the same direction, with weakening prescriber clout and thus also less impact from detailing on launch success.
You may also be interested in...
Personalizing Patient Care:Sanofi Recasts Its Diabetes Efforts
In a bid to protect its most valuable product, Lantus, Sanofi’s new diabetes division intends to provide holistic solutions in an effort to help patients better manage their disease. Will it work?
Personalizing Patient Care:Sanofi Recasts Its Diabetes Efforts
In a bid to protect its most valuable product, Lantus, Sanofi’s new diabetes division intends to provide holistic solutions in an effort to help patients better manage their disease. Will it work?
The Cost-Sharing Solution: The New NICE Ticket
J&J's Velcade and Celgene's Revlimid illustrate how pharma has adapted to the NICE UK cost-effectiveness watchdog. Now that the UK precedents exist, there will be more to come. But are they really pharma's ticket to increased access, and do they assure the value to the health care system that they claim? This article originally appeared in February 2009's RPM Report.